A new daily pill may offer a sustainable solution for maintaining weight loss after patients stop using expensive injectable medications, according to landmark trial data. The study suggests that orforglipron, an oral medication, can help prevent the significant weight regain often seen when patients discontinue weekly GLP-1 injections like Wegovy or Mounjaro.
This development is significant not just for weight management, but for broader public health. By helping people maintain a healthier weight, the pill could reduce the need for multiple other medications used to treat conditions associated with obesity, such as high blood pressure, diabetes, and high cholesterol.
The Challenge of Long-Term Weight Maintenance
Obesity affects approximately 30% of adults in the UK, and current treatments present a complex dilemma. While injectable GLP-1 agonists (such as semaglutide and tirzepatide) are highly effective, causing patients to lose 15–20% of their body weight, they come with substantial drawbacks:
- High Cost: These drugs are expensive for both private purchasers and national health systems like the NHS.
- Treatment Burden: Weekly injections require storage, travel for appointments, and long-term commitment.
- Weight Regain: Previous studies indicate that most patients regain two-thirds of their lost weight within a year of stopping the injections.
“Many people do not want to remain on injectable therapy indefinitely due to treatment burden, convenience, travel, storage requirements, cost or personal preference,” said Dr. Marie Spreckley from the University of Cambridge.
Trial Results: Switching to Oral Therapy
The new trial, published in Nature Medicine and presented at the European Congress on Obesity 2026, investigated whether switching to oral orforglipron could mitigate weight regain.
Researchers followed 376 US patients who had been on tirzepatide (Mounjaro) or semaglutide (Wegovy) for 72 weeks. After this period, patients were switched to either daily orforglipron pills or a placebo for one year. The results were striking:
- Tirzepatide Users: Patients who switched to orforglipron retained 75% of their lost weight, compared to only 49% for those on the placebo.
- Semaglutide Users: Patients maintained 80% of their previous weight loss, whereas the placebo group retained only 38%.
Crucially, the study found that switching to the pill did not just preserve weight loss; it also maintained improvements in blood pressure, cholesterol, and blood sugar levels.
Treating Obesity as a Chronic Disease
The findings support a shifting medical perspective: treating obesity not merely as a lifestyle issue, but as a chronic disease with systemic effects.
Dr. Louis Aronne, director of the Comprehensive Weight Control Center at Weill Cornell Medicine, emphasized the broader benefits of this approach. He noted that the average patient in their clinics has a BMI of 38, suffers from sleep apnea, and takes seven different medications to manage various health conditions.
“The beauty of treating obesity is you are treating all of these things: you treat the glucose, treat the lipids, treat the blood pressure, all by treating the obesity,” Aronne said. He argued that effective obesity treatment could eliminate the need for separate cardio-metabolic risk factor medications.
A More Accessible Future?
While injectable drugs generally produce greater weight loss, their cost limits long-term applicability. Dr. Simon Cork from Anglia Ruskin University noted that newer oral medications are significantly cheaper to manufacture. Although they may not induce as rapid or extensive weight loss as injections, their ability to maintain results offers a viable alternative for long-term care.
“This limits their long-term applicability both for private purchasers and the NHS,” Cork said of the injectables, adding that oral options could represent a “potential future for how patients with obesity are treated.”
Conclusion
The trial demonstrates that oral orforglipron can effectively help patients maintain the majority of their weight loss after stopping GLP-1 injections. This offers a more affordable and convenient long-term strategy for managing obesity, potentially reducing the burden of comorbid diseases and the need for multiple concurrent medications.
